Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma
Sylvie Négrier, Bernard J. Escudier, Christine Lasset et al. · New England Journal of Medicine · 1998
BACKGROUND: Recombinant human interleukin-2 (aldesleukin) and recombinant human interferon alfa can induce notable tumor regression in a limited number of patients with metastatic renal-cell carcinoma. We conducted a multicenter, randomized trial to determine the effect of each cytokine independently and in combination, and to identify patients who are best suited for this treatment. METHODS: Four hundred twenty-five patients with metastatic renal-cell carcinoma were randomly assigned to receive either a continuous intravenous infusion of interleukin-2, subcutaneous injections of interferon alfa-2a, or both. The main outcome measure was the response rate; secondary outcomes were the rates of event-free and overall survival. Predictive factors for response and rapid progression were identified by multivariate analysis. RESULTS: Response rates were 6.5 percent, 7.5 percent, and 18.6 percent (P<0.01) for the groups receiving interleukin-2, interferon alfa-2a, and interleukin-2 plus interferon alfa-2a, respectively. At one year, the event-free survival rates were 15 percent, 12 percent, and 20 percent, respectively (P=0.01). There was no significant difference in overall survival among the three groups. Toxic effects of therapy were more common in patients receiving interleukin-2 than in those receiving interferon alfa-2a. Response to treatment was associated with having metastasis to a single organ and with receiving the combined treatment. The probability of rapid progression of disease was at least 70 percent for patients with at least two metastatic sites, liver metastases, and a period of less than one year between the diagnosis of the primary tumor and the appearance of metastases. CONCLUSIONS: Cytokines are active in a few patients with metastatic renal-cell carcinoma. The higher response rate and longer event-free survival obtained with a combination of cytokines must be balanced against the toxicity of such treatment.
Cited by 967 works. doi:10.1056/nejm199804303381805 Open-access PDF
Authors
- Sylvie Négrier
- Bernard J. Escudier
- Christine Lasset
- Jean‐Yves Douillard
- Christine Chevreau
- Alain Ravaud
- Alain Mercatello
- J Pény
- Mireille Mousseau
- Thierry O. Philip
- Thomas Tursz
References
- Nonparametric Estimation from Incomplete Observations
- Evaluation of survival data and two new rank order statistics arising in its consideration.
- Nonparametric Estimation from Incomplete Observations
- Reporting results of cancer treatment
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
- Renal-Cell Carcinoma
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
- The Natural History of Metastatic Renal Cell Carcinoma: A Computer Analysis
- Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.